Royal Bank of Canada set a €130.00 ($151.16) price target on MorphoSys (ETR:MOR) in a research report released on Tuesday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the stock.
A number of other research firms also recently issued reports on MOR. Independent Research set a €110.00 ($127.91) price target on MorphoSys and gave the company a neutral rating in a research report on Friday, November 1st. Deutsche Bank set a €129.00 ($150.00) price objective on MorphoSys and gave the stock a buy rating in a report on Friday, December 6th. JPMorgan Chase & Co. set a €130.00 ($151.16) price objective on MorphoSys and gave the company a buy rating in a research note on Monday, November 18th. Berenberg Bank set a €145.00 ($168.60) target price on MorphoSys and gave the stock a buy rating in a report on Tuesday. Finally, HSBC set a €81.00 ($94.19) target price on shares of MorphoSys and gave the stock a sell rating in a research report on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average target price of €119.86 ($139.37).
Shares of MOR opened at €123.40 ($143.49) on Tuesday. The company has a current ratio of 7.80, a quick ratio of 7.63 and a debt-to-equity ratio of 9.78. The firm has a market capitalization of $3.91 billion and a P/E ratio of -40.57. The stock’s fifty day simple moving average is €104.58 and its 200 day simple moving average is €99.76. MorphoSys has a twelve month low of €79.70 ($92.67) and a twelve month high of €118.90 ($138.26).
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Recommended Story: What is the Difference Between Common Shares and Convertible Shares?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.